Sagimet Biosciences (SGMT) Research & Development (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Research & Development of $7.0 million for Q1 2026, down 54.41% year-over-year from $15.3 million in Q1 2025, and up 3.88% quarter-over-quarter from $6.7 million in Q4 2025.
Sagimet Biosciences (SGMT) Research & Development (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Research & Development history runs 5 years deep, the most recent figure standing at $7.0 million for Q1 2026.
- In Q1 2026, Research & Development fell 54.41% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $30.7 million (down 36.72% YoY), while the FY2025 annual figure was $39.1 million, up 1.59% from the prior year.
- Research & Development for Q1 2026 stood at $7.0 million, up from $6.7 million in the prior quarter.
- The five-year high for Research & Development was $15.3 million in Q1 2025, with the low at $4.5 million in Q1 2023.
- The 5-year median for Research & Development is $6.6 million (2022), against an average of $7.7 million.
- The sharpest annual moves came in 2025 and 2026: Research & Development surged 191.56% in 2025, then sank 54.41% in 2026.
- Sagimet Biosciences' Research & Development stood at $5.8 million in 2022, then slipped by 3.27% to $5.7 million in 2023, then surged by 151.34% to $14.2 million in 2024, then tumbled by 52.63% to $6.7 million in 2025, then grew by 3.88% to $7.0 million in 2026.
- Business Quant data shows SGMT's Research & Development at $7.0 million in Q1 2026, $6.7 million in Q4 2025, and $9.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 11.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.54 Mn |
| Mar 31, 2026 | 7.00 Mn |
| Dec 31, 2025 | 6.73 Mn |
| Sep 30, 2025 | 9.73 Mn |
| Jun 30, 2025 | 7.25 Mn |
| Mar 31, 2025 | 15.34 Mn |
| Dec 31, 2024 | 14.22 Mn |
| Sep 30, 2024 | 12.65 Mn |
| Jun 30, 2024 | 6.31 Mn |
| Mar 31, 2024 | 5.26 Mn |
| Dec 31, 2023 | 5.66 Mn |
| Sep 30, 2023 | 4.96 Mn |
| Jun 30, 2023 | 4.68 Mn |
| Mar 31, 2023 | 4.49 Mn |
| Dec 31, 2022 | 5.85 Mn |
| Sep 30, 2022 | 6.84 Mn |
| Jun 30, 2022 | 6.37 Mn |